Affordable Access

deepdyve-link
Publisher Website

New potential therapeutic approaches in frontotemporal dementia: oxytocin, vasopressin, and social cognition.

Authors
  • Finger, Elizabeth C1
  • 1 Department of Clinical Neurological Sciences, Schulich School of Medicine, University of Western Ontario, B10-004, 339 Windermere Rd, London, ON, N6A 5A5, Canada. [email protected] , (Canada)
Type
Published Article
Journal
Journal of Molecular Neuroscience
Publisher
Springer-Verlag
Publication Date
Nov 01, 2011
Volume
45
Issue
3
Pages
696–701
Identifiers
DOI: 10.1007/s12031-011-9550-2
PMID: 21618004
Source
Medline
License
Unknown

Abstract

Frontotemporal dementias are neurodegenerative disorders marked by mid-life onset and progressive changes in behavior, decision making, and/or language. In several subtypes of frontotemporal dementia (FTD), damage to regions of the frontal and temporal lobes that occurs early in the disease course critically impairs emotional processing, social cognition, and behavior. To date, there are no curative or disease-modifying treatments for FTD, nor any approved treatments for the loss of empathy, impaired social cognition, and behavior of patients with FTD. A growing body of research suggests that the neuropeptides oxytocin and vasopressin are important mediators of social behavior in humans and other animals. Here, we review the effects of oxytocin and vasopressin on social cognition and behavior and discuss the potential implications for these agents as novel treatments in FTD.

Report this publication

Statistics

Seen <100 times